Biotech Values

[dewophile]

we will probably get a chance to see the data in pts with higher PD-1 expression since this was a prespecified endpoint.
This might down the road be water under the bridge if data on combo w chemo or other IO combos works out. The massive swings in valuation obviously show how much of BMY's market cap is tied to opdivo. with so many PD-1s in so many combinations who the hell knows how the commercial landscape will wind up - clearly risk here for those who are currently leaders (it's why crazy sums are paid like bmy's 800M for a preclinical compound from flexus)